Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958241 | 1.00 | KMT2A (0.50) | KMT2AMEN1LMNACYP2D6HRH1 | |
| SCHEMBL4396455 | 1.00 | KMT2A (0.50) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Hydrochloric Acid SCHEMBL10869034 | 0.98 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Bromide SCHEMBL4505514 | 0.98 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Bromide SCHEMBL4505510 | 0.98 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Maleic Acid SCHEMBL10360499 | 0.93 | HRH1 (0.44) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL5085962 | 0.92 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL1975758 | 0.92 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL1975759 | 0.92 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| SCHEMBL8424910 | 0.91 | KEAP1 (0.43) | KMT2AMEN1LMNACYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238129-B1 | A METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | ZENTIVA KS (CZ) | 2011-08-17 | — | — | EP | claimed |
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | Watson Pharma Private Limited (IN) | 2011-06-16 | — | — | US | claimed |
| US-20100317871-A1 | METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | ZENTIVA K.S. (CZ) | 2010-12-16 | — | — | US | claimed |
| EP-2238129-A1 | A METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | Zentiva, K.S. (CZ) | 2010-10-13 | — | — | EP | claimed |
| EP-2160372-A1 | METHOD FOR DETERMINING ENANTIOMERIC PURITY OF DARIFENACIN AND INTERMEDIATES | Medichem, S.A. (ES) | 2010-03-10 | — | — | EP | claimed |
| WO-2009094957-A1 | A METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | ZENTIVA, K.S. (CZ) | 2009-08-06 | — | — | WO | claimed |
| WO-2008152497-A1 | METHOD FOR DETERMINING ENANTIOMERIC PURITY OF DARIFENACIN AND INTERMEDIATES | MEDICHEM, S.A. (US) | 2008-12-18 | — | — | WO | claimed |
| EP-1891034-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-27 | — | — | EP | claimed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | claimed |
| WO-2007076157-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| EP-0178947-B1 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-09-26 | — | — | EP | claimed |
| EP-0178947-A2 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | claimed |
| EP-0178946-A2 | 1-(Aminoalkyl)-alpha, alpha-diaryl pyrrolidine-piperidine- and homopiperidine- acetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | claimed |
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| EP-0178946-A2 | 1-(Aminoalkyl)-alpha, alpha-diaryl pyrrolidine-piperidine- and homopiperidine- acetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | disclosed |
| US-4260606-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4242261-A | REACTING AN A,A-DIPHENYL-A-N-HETEROCYCLIC ACETAMIDE WITH BROMINE AND AN ALKALI METAL ALKOXIDE AND HEATING | A. H. ROBINS COMPANY, INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4133881-A | Azetidinyl acetonitrile and acetamide antiarrhythmia compositions and methods | A. H. ROBINS COMPANY, INCORPORATED (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317871-A1 | METHOD FOR THE PREPARATION OF DARIFENACIN HYDROGEN BROMIDE | OPRD1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OPRK1 | KMT2A 3646/4885MEN1 3969/4885LMNA 1495/4885 |
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | OPRL1, OPRD1, OPRK1 | KMT2A 4630/4885MEN1 4026/4885LMNA 2737/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | KMT2A 3578/4885MEN1 2021/4885LMNA 2545/4885 |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | KMT2A 491/4885MEN1 3204/4885LMNA 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.